THG Digital 11/9/26 THG Digital 11/9/26

CVS’ split doesn’t fix its fundamental problem

THG Digital 11/6/26 THG Digital 11/6/26

Don’t Ban U.S. Biotech Companies From China

THG Digital 11/4/26 THG Digital 11/4/26

The COINS Act: Penny Wise, Patient Foolish

THG Digital 11/3/26 THG Digital 11/3/26

GLOBE: A World of Bad Ideas for American Patients

THG Digital 10/26/26 THG Digital 10/26/26

Update on Foreign Freeloading on American Drug Innovation

THG Digital 10/22/26 THG Digital 10/22/26

Heard on the Hill: GRADES ARE IN

THG Digital 10/15/26 THG Digital 10/15/26

Beware the Post-Midterm Price Control Creep

THG Digital 10/9/26 THG Digital 10/9/26

How MFN pricing in the final GLOBE Model will affect beneficiary OOP costs

THG Digital 10/1/26 THG Digital 10/1/26

Emulating European healthcare won’t win America the biotech race

THG Digital 10/1/26 THG Digital 10/1/26

Medicare Advantage plans shift more costs onto seniors in 2027

THG Digital 9/28/26 THG Digital 9/28/26

AARP’s $200 billion mirage: How price controls kill tomorrow’s medicine

THG Digital 9/25/26 THG Digital 9/25/26

MFN Drug Pricing Won’t Help, But Competition Will

THG Digital 9/21/26 THG Digital 9/21/26

If Trump wants to lower drug prices, his obvious free-riding targets are outside the US

THG Digital 9/17/26 THG Digital 9/17/26

American patients shouldn’t foot the bill for the world’s medicines

THG Digital 9/16/26 THG Digital 9/16/26

The Inflation Reduction Act’s broken promise is still costing patients

News & Resources

CVS’ split doesn’t fix its fundamental problem

Don’t Ban U.S. Biotech Companies From China

The COINS Act: Penny Wise, Patient Foolish

GLOBE: A World of Bad Ideas for American Patients

Update on Foreign Freeloading on American Drug Innovation

Heard on the Hill: GRADES ARE IN

Beware the Post-Midterm Price Control Creep

How MFN pricing in the final GLOBE Model will affect beneficiary OOP costs

Emulating European healthcare won’t win America the biotech race

Medicare Advantage plans shift more costs onto seniors in 2027

AARP’s $200 billion mirage: How price controls kill tomorrow’s medicine

MFN Drug Pricing Won’t Help, But Competition Will

If Trump wants to lower drug prices, his obvious free-riding targets are outside the US

American patients shouldn’t foot the bill for the world’s medicines

The Inflation Reduction Act’s broken promise is still costing patients

ACT Now for a Healthier, Stronger America!